Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.16p
   
  • Change Today:
    -0.011p
  • 52 Week High: 0.75
  • 52 Week Low: 0.16
  • Currency: UK Pounds
  • Shares Issued: 1,320.30m
  • Volume: 5,409,883
  • Market Cap: £2.11m
  • RiskGrade: 435

Deal with Barclays    Trade now with Barclays Stockbrokers

Valirx Overview

ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -7630.8% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 73.5 n/a
Pr/Book 1.0  
Latest F'cast
Revenue -36.3% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Valirx Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 n/a (1.68) (2.34)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (2.60) (3.06)p n/a n/a n/a n/a 0.0%
31-Dec-23 0.01 (2.30) (2.01)p n/a n/a n/a n/a 0.0%
31-Dec-24 0.05 (2.13) (1.45)p n/a n/a n/a n/a 0.0%
31-Dec-25 0.03 (2.42) (0.54)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Valirx Company Announcements

Conclusion of Evaluation with University of Dundee 22-Jun-2026 07:00 RNS
Final Results & Notice of AGM 22-Jun-2026 07:00 RNS
Conclusion of Evaluation with Stingray 02-Jun-2026 07:00 RNS

Valirx ShareCast News

ValiRx launches prostate cancer subsidiary Blue ... 26-Aug-2025 ShareCast
Ambrose exercises ValiRx oncology option worth u... 20-Jun-2025 ShareCast
ValiRx terminates exclusive negotiations with Th... 03-Apr-2025 ShareCast

Valirx Top Newspaper Links

Business Digest 24-Sep-2006 Sunday Times

Latest Valirx Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Valirx Market Data

Currency UK Pounds
Share Price 0.16p
Change Today -0.011p
% Change -6.16 %
52 Week High 0.75
52 Week Low 0.16
Volume 5,409,883
Shares Issued 1,320.30m
Market Cap £2.11m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
41.52% above the market average41.52% above the market average41.52% above the market average41.52% above the market average41.52% above the market average
46.34% above the sector average46.34% above the sector average46.34% above the sector average46.34% above the sector average46.34% above the sector average
Price Trend
87.83% below the market average87.83% below the market average87.83% below the market average87.83% below the market average87.83% below the market average
81.82% below the sector average81.82% below the sector average81.82% below the sector average81.82% below the sector average81.82% below the sector average
Income Not Available
Growth
26.62% above the market average26.62% above the market average26.62% above the market average26.62% above the market average26.62% above the market average
31.03% above the sector average31.03% above the sector average31.03% above the sector average31.03% above the sector average31.03% above the sector average

Valirx Dividends

No dividends found

Trades for 03-Jul-2026

Time Volume / Share Price
16:48 4,900,000 @ 0.16p
16:08 500,000 @ 0.16p
14:23 9,883 @ 0.16p

Valirx Key Personnel

CFO Gerald Desler

Top of Page